ヒト化マウス・ラットモデル市場：タイプ別（遺伝子モデル、細胞ベースモデル（CD34、BLT、PMC）、ラットモデル）、用途別（腫瘍学、免疫学、神経科学、毒性学、感染症）、エンドユーザー別（製薬、バイオテクノロジー）、地域別 - 2028年までの世界予測

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models (CD34, BLT, PMC), Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech) & Region - Global Forecast to 2028

世界のヒト化マウス・ラットモデル市場は、2023年の2億5,900万米ドルから2028年には3億4,900万米ドルに達すると予測され、2023年から2028年の予測期間中のCAGRは6.2%である。CRISPRは、手頃な価格とCRISPRに関連... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年7月21日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	206	221	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

世界のヒト化マウス・ラットモデル市場は、2023年の2億5,900万米ドルから2028年には3億4,900万米ドルに達すると予測され、2023年から2028年の予測期間中のCAGRは6.2%である。CRISPRは、手頃な価格とCRISPRに関連する迅速な結果に起因して、遺伝子改変マウス系統を開発するために大きな需要を獲得するように設定されている。CRISPRは、効率的な遺伝子ヒト化マウスモデルの開発、遺伝子改変のための市場プレーヤーにとって強力な遺伝子編集技術として浮上している。
ヒト化マウスモデル分野は、2022年の市場で最も高い収益シェアを占めた。
タイプ別では、ヒト化マウス・ラットモデル市場は、ヒト化マウスモデルとヒト化ラットモデルに区分される。2022年には、ヒト化マウスモデルが市場で最も高い収益シェアを獲得している。また、このセグメントは予測期間を通じて最も速いCAGRで成長すると予測されている。細胞ベースのヒト化マウスモデルに対する需要の増加が、このセグメントの成長に寄与している。これらのモデルは、潜在的な新薬の安全性や有効性の分析、免疫腫瘍学、感染症、移植片対宿主病などの分野における長期研究など、幅広い用途に使用されている。
免疫・感染症分野は、2022年の市場で第2位のシェアを占めた。
用途別では、ヒト化マウス・ラットモデル市場は、腫瘍学、免疫・感染症、神経科学、造血、毒物学、その他の用途に区分される。免疫・感染症分野は、売上高で市場第2位の分野である。マウスモデルは、実験的知見の生理学的妥当性を評価するのに役立つため、免疫学や炎症研究で使用される。マウスモデルは、マウスのゲノムを無作為または特定の領域で適切に変化させることができるため、免疫学的プロセスの詳細な研究が可能になる。
欧州はヒト化マウス・ラットモデル市場で2番目に大きい地域
ヒト化マウス・ラットモデル市場は、北米、欧州、アジア太平洋、中南米（LATAM）、中東・アフリカ（MEA）に区分される。癌との闘いへの注目の高まりが、市場成長を促進する重要な要因である。これは、欧州における2つの著名な組織、Cancer Core EuropeとEurOPDX Consortium（18の非営利がんセンターと大学で構成）の設立からも明らかである。

本レポートのために実施した一次インタビューは以下のように分類できる：
- 企業別-タイヤ1-37％。タイヤ2-23％、タイヤ3-40
- 役職別Cレベル：32％、ディレクターレベル：26％、その他：42
- 地域別北米35％、欧州25％、アジア太平洋地域20％、中南米12％、中東・アフリカ8
レポート掲載企業一覧
- チャールズ・リバー・ラボラトリーズ（米国）
- ザ・ジャクソン・ラボラトリー（ジャックス）（米国）
- タコニック・バイオサイエンシズ（米国）
- クラウン・バイオサイエンシズ（米）
- チャンピオンズオンコロジー（米）
- ヘラ・バイオラボ（米）
- genOway（フランス）
- イノティブ（米国）
- バイタルスター・バイオテクノロジー（中国）
- インジニアス・ターゲティング・ラボラトリー（米国）
- トランスジェニック（日本）
- ハーバー抗体BV（オランダ）
- オンコデザイン（フランス）
- Pharmatest Services（フィンランド）
- オズジーン社（オーストラリア(オーストラリア）
- トランスキュア・バイオサービス（フランス）
- サイジェン・バイオサイエンシズ（米国）
- アラジェン・ライフサイエンス社（インド(インド）
- ジェムファーマテック（中国）
- バイオサイトーゲン（米国）
調査範囲
この調査レポートは、ヒト化マウス・ラットモデル市場の詳細な姿を掲載しています。種類、用途、エンドユーザー、地域などの異なるセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主な利点
本レポートは、ヒト化マウス・ラットモデル市場全体とそのサブセグメントについて、最も近似した収益数字を提供することで、市場リーダー／新規参入者を支援します。また、ステークホルダーが競合状況をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、動向、機会に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 主な促進要因の分析（ヒト化マウス・ラットモデル市場の成長は、創薬研究におけるヒト化モデルの使用の増加、個別化医療に対する需要の高まり、がん研究に対する政府出資のイニシアチブ、製薬・バイオテクノロジー産業における研究開発活動の増加が主な要因）、阻害要因（カスタムヒト化モデルの高コスト、ヒト化マウスモデルに対する需要の高まり、ヒト化PDXモデルに対する嗜好、生物医学研究におけるCRISPRの出現）、課題（ヒト化マウスモデルの限界、動物実験の代替方法）がヒト化マウス・ラットモデル市場の成長に影響を与えている。
- 製品開発/イノベーション：新たに発売された製品に関する詳細な洞察、ヒト化マウス・ラットモデル市場の技術評価。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域のヒト化マウス・ラットモデル市場を分析しています。
- 市場の多様化：新製品、未開拓の地域、最近の開発、ヒト化マウス・ラットモデル市場への投資に関する詳細な情報を提供します。
- 競合評価：Charles River Laboratories社（米国）、THE JACKSON LABORATORY (JAX)社（米国）、Taconic Biosciences, Inc.社（米国）、Inotiv社（米国）など、ヒト化マウス・ラットモデル市場における主要企業の市場シェア、成長戦略、製品提供を詳細に評価します。また、本レポートは、関係者がヒト化マウス・ラットモデル市場のパルスを理解するのに役立ち、主要な市場促進要因、阻害要因、課題、機会に関する情報を提供します。

ページTOPに戻る

1 INTRODUCTION 31
1.1 STUDY OBJECTIVES 31
1.2 MARKET DEFINITION 31
1.2.1 INCLUSIONS AND EXCLUSIONS 32
1.3 MARKET SCOPE 32
1.3.1 MARKETS COVERED 32
1.3.2 YEARS CONSIDERED 33
1.4 CURRENCY CONSIDERED 33
1.5 LIMITATIONS 33
1.6 STAKEHOLDERS 34
1.7 SUMMARY OF CHANGES 34
2 RESEARCH METHODOLOGY 35
2.1 RESEARCH APPROACH 35
FIGURE 1 RESEARCH DESIGN 35
2.1.1 SECONDARY DATA 36
2.1.2 PRIMARY DATA 36
2.1.2.1 Breakdown of primary sources 37
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 37
2.2 PRIMARY INSIGHTS 38
2.3 MARKET SIZE ESTIMATION 38
FIGURE 3 HUMANIZED MOUSE AND RAT MODEL MARKET: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS) 38
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) 39
2.4 MARKET GROWTH RATE PROJECTIONS 41
FIGURE 5 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS 41
FIGURE 6 HUMANIZED MOUSE AND RAT MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 42
2.4.1 DATA TRIANGULATION AND MARKET BREAKDOWN 43
FIGURE 7 DATA TRIANGULATION METHODOLOGY 43
2.5 RESEARCH ASSUMPTIONS 44
2.6 RISK IMPACT ANALYSIS 44
2.7 RECESSION IMPACT ANALYSIS 44
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 45
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 45
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 45

3 EXECUTIVE SUMMARY 46
FIGURE 8 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 46
FIGURE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 47
FIGURE 10 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF HUMANIZED MOUSE AND RAT MODEL MARKET 48
4 PREMIUM INSIGHTS 50
4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW 50
FIGURE 12 RISING USE OF HUMANIZED MODELS IN DRUG DISCOVERY RESEARCH TO DRIVE MARKET 50
4.2 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY 51
FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN CHINA FOR 2022 51
4.3 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE (USD MILLION) 52
FIGURE 14 PBMC HUMANIZED MOUSE MODELS SEGMENT TO REGISTER HIGHER GROWTH RATE DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 15 HUMANIZED MOUSE AND RAT MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Rising use of humanized models in drug discovery research 54
5.2.1.2 Growing preference for personalized medicine 54
5.2.1.3 Government-funded initiatives for cancer research 55
5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industries 56
TABLE 4 NUMBER OF R&D PRODUCTS, BY INDICATION (2022) 56
5.2.2 RESTRAINTS 57
5.2.2.1 High cost of custom humanized models 57
5.2.2.2 Stringent regulatory compliance for ethical use of animal models 57
5.2.3 OPPORTUNITIES 58
5.2.3.1 Growing preference for humanized PDX models 58
5.2.3.2 Emergence of CRISPR in biomedical research 58
5.2.3.3 Rising demand for humanized rat models 58
5.2.4 CHALLENGES 59
5.2.4.1 Alternative methods for animal testing 59
5.2.4.2 Limitations of humanized mouse models 59
5.3 REGULATORY ANALYSIS 60
5.3.1 NORTH AMERICA 60
5.3.2 EUROPE 61
5.3.3 ASIA PACIFIC 62
5.3.3.1 China 62
5.3.3.2 Japan 63
5.3.3.3 India 63
5.3.3.4 Australia 64
5.3.4 LATIN AMERICA 64
5.3.5 MIDDLE EAST & AFRICA 64
5.4 PRICING ANALYSIS 65
TABLE 5 PRICE OF HUMANIZED MOUSE MODELS (2022) 65
5.5 TECHNOLOGY ANALYSIS 65
5.6 VALUE CHAIN ANALYSIS 66
FIGURE 16 CREATION OF HUMANIZED MODELS—MAXIMUM VALUE IS ADDED DURING IMPLANTATION OF GRAFT/TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS 66
5.7 ECOSYSTEM ANALYSIS 67
FIGURE 17 HUMANIZED MOUSE AND RAT MODEL MARKET: ECOSYSTEM MAP 67
TABLE 6 SUPPLY CHAIN ECOSYSTEM 67
5.8 PORTER’S FIVE FORCES ANALYSIS 68
TABLE 7 HUMANIZED MOUSE AND RAT MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS 68
5.8.1 THREAT OF NEW ENTRANTS 69
5.8.2 THREAT OF SUBSTITUTES 69
5.8.3 BARGAINING POWER OF BUYERS 69
5.8.4 BARGAINING POWER OF SUPPLIERS 69
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 69
5.9 PATENT ANALYSIS 70
5.10 KEY CONFERENCES AND EVENTS 71
5.10.1 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023 71
TABLE 8 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY CONFERENCES AND EVENTS IN 2023 71
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 72
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 72
FIGURE 18 HUMANIZED MOUSE AND RAT MODEL MARKET: INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS 72
5.11.2 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY BUYING CRITERIA 72
FIGURE 19 KEY BUYING CRITERIA FOR END USERS 72

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE 73
6.1 INTRODUCTION 74
TABLE 9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 74
6.2 HUMANIZED MOUSE MODELS 74
TABLE 10 HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 75
TABLE 11 HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 75
TABLE 12 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 13 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
TABLE 14 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 76
6.2.1 GENETIC HUMANIZED MOUSE MODELS 77
6.2.1.1 Advancements in genetic engineering technologies to drive market 77
TABLE 15 GENETIC HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 16 NORTH AMERICA: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 17 EUROPE: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 18 ASIA PACIFIC: GENETIC HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
6.2.2 CELL-BASED HUMANIZED MOUSE MODELS 79
TABLE 19 CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 79
TABLE 20 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 21 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
TABLE 22 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.2.2.1 CD34 humanized mouse models 80
6.2.2.1.1 Rising demand for stem cell therapy to propel market 80
TABLE 23 CD34 HUMANIZED MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 24 NORTH AMERICA: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 25 EUROPE: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 82
TABLE 26 ASIA PACIFIC: CD34 HUMANIZED MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
6.2.2.2 PBMC humanized mouse models 83
6.2.2.2.1 Growing prevalence of infectious diseases to fuel uptake 83
TABLE 27 PBMC HUMANIZED MICE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 28 NORTH AMERICA: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 29 EUROPE: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 30 ASIA PACIFIC: PBMC HUMANIZED MICE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.2.2.3 BLT humanized mouse models 85
6.2.2.3.1 Increasing HIV cases to propel market 85
TABLE 31 BLT HUMANIZED MOUSE MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 32 NORTH AMERICA: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 33 EUROPE: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
TABLE 34 ASIA PACIFIC: BLT HUMANIZED MOUSE MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.3 HUMANIZED RAT MODELS 87
6.3.1 ABILITY TO SUSTAIN HIGH INTRAVENOUS DOSING TO SUPPORT MARKET GROWTH 87
TABLE 35 HUMANIZED RAT MODELS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 36 NORTH AMERICA: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 37 EUROPE: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
TABLE 38 ASIA PACIFIC: HUMANIZED RAT MODELS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION 90
7.1 INTRODUCTION 91
TABLE 39 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 91
7.2 ONCOLOGY 91
7.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO PROPEL MARKET 91
TABLE 40 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 41 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 42 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 43 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ONCOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 94
7.3 IMMUNOLOGY AND INFECTIOUS DISEASES 94
7.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET 94
TABLE 44 HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 45 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 46 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 47 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR IMMUNOLOGY AND INFECTIOUS DISEASES, BY COUNTRY, 2021–2028 (USD MILLION) 96
7.4 NEUROSCIENCE 96
7.4.1 RISING INCIDENCE OF CNS DISORDERS TO PROPEL MARKET 96
TABLE 48 HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY REGION, 2021–2028 (USD MILLION) 97
TABLE 49 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 50 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION) 97
TABLE 51 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR NEUROSCIENCE, BY COUNTRY, 2021–2028 (USD MILLION) 98
7.5 TOXICOLOGY 98
7.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH 98
TABLE 52 HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 53 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 54 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 55 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR TOXICOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 100
7.6 HEMATOPOIESIS 100
7.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET 100
TABLE 56 HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 57 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 58 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 59 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR HEMATOPOIESIS, BY COUNTRY, 2021–2028 (USD MILLION) 102
7.7 OTHER APPLICATIONS 102
TABLE 60 HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 103
TABLE 61 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 62 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 63 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 104
8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER 105
8.1 INTRODUCTION 106
TABLE 64 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 106
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 106
8.2.1 INCREASING EXPENDITURE ON R&D FOR DRUG DEVELOPMENT TO DRIVE MARKET 106
TABLE 65 HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 66 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 67 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 68 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 109
8.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS 109
8.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET 109
TABLE 69 HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY REGION, 2021–2028 (USD MILLION) 110
TABLE 70 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 71 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION) 110
TABLE 72 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR CROS AND CDMOS, BY COUNTRY, 2021–2028 (USD MILLION) 111
8.4 ACADEMIC & RESEARCH INSTITUTES 111
8.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO SUPPORT MARKET GROWTH 111
TABLE 73 HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 112
TABLE 74 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 75 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 76 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 113

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION 114
9.1 INTRODUCTION 115
TABLE 77 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION) 115
9.2 NORTH AMERICA 115
FIGURE 20 HUMANIZED MOUSE AND RAT MODEL MARKET: NORTH AMERICA SNAPSHOT 116
TABLE 78 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 79 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 80 NORTH AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 81 NORTH AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 82 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 118
TABLE 83 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.2.1 US 118
9.2.1.1 Growing research initiatives on mAbs and biosimilars to drive market 118
TABLE 84 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 85 US: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 86 US: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 87 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 120
TABLE 88 US: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 121
9.2.2 CANADA 121
9.2.2.1 Government initiatives on stem cell research to drive market 121
TABLE 89 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 90 CANADA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 91 CANADA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 92 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 123
TABLE 93 CANADA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 123
9.2.3 NORTH AMERICA: RECESSION IMPACT 123
9.3 EUROPE 124
TABLE 94 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 95 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 96 EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 97 EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 98 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 126
TABLE 99 EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 126
9.3.1 GERMANY 126
9.3.1.1 Rising pharmaceutical R&D expenditure to drive market 126
TABLE 100 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 101 GERMANY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 102 GERMANY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 128
TABLE 103 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 128
TABLE 104 GERMANY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 129
9.3.2 UK 129
9.3.2.1 Growing investments in cancer research to drive market 129
TABLE 105 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 106 UK: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 107 UK: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 108 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 131
TABLE 109 UK: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 131
9.3.3 FRANCE 131
9.3.3.1 Increasing initiatives for genomics research to support market growth 131
TABLE 110 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 111 FRANCE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 112 FRANCE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 113 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 133
TABLE 114 FRANCE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 134
9.3.4 ITALY 134
9.3.4.1 Rising R&D spending on pharmaceutical production to fuel market 134
TABLE 115 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 116 ITALY: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 117 ITALY: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 118 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 136
TABLE 119 ITALY: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 136
9.3.5 SPAIN 136
9.3.5.1 Rising growth in biotech industry to drive market 136
TABLE 120 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 121 SPAIN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 122 SPAIN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 138
TABLE 123 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 138
TABLE 124 SPAIN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 139
9.3.6 REST OF EUROPE 139
TABLE 125 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 126 REST OF EUROPE: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 127 REST OF EUROPE: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 128 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140
TABLE 129 REST OF EUROPE: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 141
9.3.7 EUROPE: RECESSION IMPACT 141
9.4 ASIA PACIFIC 141
FIGURE 21 HUMANIZED MOUSE AND RAT MODEL MARKET: ASIA PACIFIC SNAPSHOT 142
TABLE 130 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 143
TABLE 131 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 132 ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 143
TABLE 133 ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 144
TABLE 134 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 144
TABLE 135 ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 145
9.4.1 CHINA 145
9.4.1.1 High growth in pharmaceutical industry to drive market 145
TABLE 136 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 137 CHINA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 146
TABLE 138 CHINA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 147
TABLE 139 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 147
TABLE 140 CHINA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 148
9.4.2 JAPAN 148
9.4.2.1 Growing research collaborations among pharmaceutical companies to drive market 148
TABLE 141 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 142 JAPAN: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 143 JAPAN: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 149
TABLE 144 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150
TABLE 145 JAPAN: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 150
9.4.3 INDIA 150
9.4.3.1 Growth in biotech industry to drive market 150
TABLE 146 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 151
TABLE 147 INDIA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 148 INDIA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 152
TABLE 149 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 152
TABLE 150 INDIA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 153
9.4.4 SOUTH KOREA 153
9.4.4.1 Rising government-funded investments for pharmaceutical R&D to drive market 153
TABLE 151 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 152 SOUTH KOREA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 153 SOUTH KOREA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 154
TABLE 154 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155
TABLE 155 SOUTH KOREA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 155
9.4.5 REST OF ASIA PACIFIC 155
TABLE 156 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 157 REST OF ASIA PACIFIC: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 156
TABLE 158 REST OF ASIA PACIFIC: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 157
TABLE 159 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 157
TABLE 160 REST OF ASIA PACIFIC: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 158
9.4.6 ASIA PACIFIC: RECESSION IMPACT 158
9.5 LATIN AMERICA 158
9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET 158
TABLE 161 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 162 LATIN AMERICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 159
TABLE 163 LATIN AMERICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 160
TABLE 164 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160
TABLE 165 LATIN AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 161
9.5.2 LATIN AMERICA: RECESSION IMPACT 161
9.6 MIDDLE EAST & AFRICA 161
9.6.1 RISING INITIATIVES FOR CLINICAL TESTING TO SUPPORT MARKET GROWTH 161
TABLE 166 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 167 MIDDLE EAST & AFRICA: HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 162
TABLE 168 MIDDLE EAST & AFRICA: CELL-BASED HUMANIZED MOUSE MODELS MARKET, BY TYPE, 2021–2028 (USD MILLION) 163
TABLE 169 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 163
TABLE 170 MIDDLE EAST & AFRICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER, 2021–2028 (USD MILLION) 164
9.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT 164

10 COMPETITIVE LANDSCAPE 165
10.1 OVERVIEW 165
10.2 STRATEGIES ADOPTED BY KEY PLAYERS 165
FIGURE 22 HUMANIZED MOUSE AND RAT MODEL MARKET: KEY STRATEGIES ADOPTED BY MARKET PLAYERS (2019−2023) 165
10.3 MARKET SHARE ANALYSIS 166
FIGURE 23 HUMANIZED MOUSE AND RAT MODEL MARKET SHARE FOR KEY PLAYERS (2022) 166
TABLE 171 HUMANIZED MOUSE AND RAT MODEL MARKET: INTENSITY OF COMPETITIVE RIVALRY 166
10.4 COMPANY EVALUATION MATRIX 167
10.4.1 STARS 168
10.4.2 EMERGING LEADERS 168
10.4.3 PERVASIVE PLAYERS 168
10.4.4 PARTICIPANTS 168
FIGURE 24 HUMANIZED MOUSE AND RAT MODEL MARKET: COMPANY EVALUATION MATRIX OF LEADING PLAYERS (2022) 169
10.5 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES 170
10.5.1 PROGRESSIVE COMPANIES 170
10.5.2 STARTING BLOCKS 170
10.5.3 RESPONSIVE COMPANIES 170
10.5.4 DYNAMIC COMPANIES 170
10.6 HUMANIZED MOUSE AND RAT MODEL MARKET: FOOTPRINT ANALYSIS OF COMPANIES 172
TABLE 172 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT FOOTPRINT ANALYSIS (2022) 172
TABLE 173 HUMANIZED MOUSE AND RAT MODEL MARKET: END-USER FOOTPRINT ANALYSIS 173
TABLE 174 HUMANIZED MOUSE AND RAT MODEL MARKET: REGIONAL FOOTPRINT ANALYSIS (2022) 174
10.7 COMPETITIVE SCENARIO AND TRENDS 174
TABLE 175 HUMANIZED MOUSE AND RAT MODEL MARKET: PRODUCT LAUNCHES 174
TABLE 176 HUMANIZED MOUSE AND RAT MODEL MARKET: DEALS 175
11 COMPANY PROFILES 176
11.1 KEY PLAYERS 176
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
11.1.1 CHARLES RIVER LABORATORIES 176
TABLE 177 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 176
FIGURE 26 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022) 177
11.1.2 THE JACKSON LABORATORY 180
TABLE 178 THE JACKSON LABORATORY: BUSINESS OVERVIEW 180
FIGURE 27 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2022) 180
11.1.3 INOTIV 183
TABLE 179 INOTIV: COMPANY OVERVIEW 183
FIGURE 28 INOTIV: COMPANY SNAPSHOT 184
11.1.4 TACONIC BIOSCIENCES, INC. 187
TABLE 180 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW 187
11.1.5 CROWN BIOSCIENCE 190
TABLE 181 CROWN BIOSCIENCE: BUSINESS OVERVIEW 190
11.1.6 CHAMPIONS ONCOLOGY, INC. 191
TABLE 182 CHAMPIONS ONCOLOGY, INC.: BUSINESS OVERVIEW 191
FIGURE 29 CHAMPIONS ONCOLOGY, INC.: COMPANY SNAPSHOT (2022) 191
11.1.7 HERA BIOLABS 193
TABLE 183 HERA BIOLABS: BUSINESS OVERVIEW 193
11.1.8 GENOWAY 194
TABLE 184 GENOWAY: BUSINESS OVERVIEW 194
11.1.9 VITALSTAR BIOTECHNOLOGY 196
TABLE 185 VITALSTAR BIOTECHNOLOGY: BUSINESS OVERVIEW 196
11.1.10 INGENIOUS TARGETING LABORATORY 197
TABLE 186 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW 197
11.1.11 TRANS GENIC 198
TABLE 187 TRANS GENIC: BUSINESS OVERVIEW 198
FIGURE 30 TRANS GENIC: COMPANY SNAPSHOT 198
11.1.12 HARBOUR ANTIBODIES BV (A SUBSIDIARY OF HARBOUR BIOMED) 200
TABLE 188 HARBOUR ANTIBODIES BV: BUSINESS OVERVIEW 200
FIGURE 31 HARBOUR BIOMED: COMPANY SNAPSHOT 200
11.1.13 ONCODESIGN 202
TABLE 189 ONCODESIGN: BUSINESS OVERVIEW 202
11.1.14 PHARMATEST SERVICES 203
TABLE 190 PHARMATEST SERVICES: BUSINESS OVERVIEW 203
11.2 OTHER PLAYERS 204
11.2.1 OZGENE PTY LTD. 204
11.2.2 TRANSCURE BIOSERVICES 204
11.2.3 CYAGEN BIOSCIENCES 205
11.2.4 ARAGEN LIFE SCIENCES LTD. (FORMERLY GVK BIO) 205
11.2.5 BIOCYTOGEN 206
11.2.6 GEMPHARMATECH 206
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX 207
12.1 DISCUSSION GUIDE 207
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 210
12.3 CUSTOMIZATION OPTIONS 212
12.4 RELATED REPORTS 212
12.5 AUTHOR DETAILS 213

ページTOPに戻る

Table of Contents

Summary

The global humanized mouse and rat model market is projected to reach USD 349 million by 2028 from USD 259 million in 2023, at a CAGR of 6.2% during the forecast period of 2023 to 2028. CRISPR is set to gain significant demand to develop genetically modified mouse strains, attributive to affordability and faster outcomes associated with CRISPR. CRISPR has emerged as a potent gene editing technology for market players for genetic modification, developing a efficient genetic humanized mouse models.
Humanized mouse models segment accounted for the highest revenue share in the market in 2022.
Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2022, humanized mouse models have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with a fastest CAGR through the forecast period. Increase in demand for cell-based humanized mouse models has contributed to the segment’s growth. These models are used for a wide range of applications, such as analyzing the safety and effectiveness of potential new drugs and in long-term studies in the fields of immuno-oncology, infectious diseases, and graft-versus-host disease.
The immunology & infectious diseases segment accounted for the second largest share of the market in 2022
Based on application, the humanized mouse and rat model market is segmented into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.
Europe is the second largest region in the humanized mouse and rat model market
The humanized mouse and rat model market is segmented into North America, Europe, Asia Pacific, Latin America (LATAM) and Middle East and Africa (MEA). A growing focus on combating cancer is a key factor driving market growth. This is evident with the formation of two prominent organizations in Europe—Cancer Core Europe and the EurOPDX Consortium (comprising 18 not-for-profit cancer centers and universities).

The primary interviews conducted for this report can be categorized as follows:
• By Company- Tire 1-37%. Tire 2-23%, Tire 3-40%
• By Designation: C Level Executives – 32%, Director level - 26%, and others-42%
• By Region: North America -35%, Europe -25%, Asia-Pacific -20%, Latin America -12%, and Middle East and Africa – 8%
List of Companies Profiled in the Report
• Charles River Laboratories (US)
• THE JACKSON LABORATORY (JAX) (US)
• Taconic Biosciences, Inc. (US)
• Crown Biosciences (US)
• Champions Oncology, Inc. (US)
• Hera BioLabs (US)
• genOway (France)
• Inotiv (US)
• Vitalstar Biotechnology (China)
• Ingenious Targeting Laboratory (US)
• TRANS GENIC (Japan)
• Harbour Antibodies BV (Netherlands)
• Oncodesign (France)
• Pharmatest Services (Finland)
• Ozgene Pty Ltd. (Australia)
• TransCure bioServices (France)
• Cyagen Biosciences (US)
• Aragen Life Sciences Ltd. (India)
• GemPharmatech (China)
• Biocytogen (US)
Research Coverage:
This report provides a detailed picture of the humanized mouse and rat model market. It aims at estimating the size and future growth potential of the market across different segments such as the type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall humanized mouse and rat model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following pointers:
• Analysis of key drivers (Growth in the humanized mouse and rat model market is majorly driven by the rising use of humanized models in drug discovery research, rising demand for personalized medicine, government-funded initiatives for cancer research, increasing R&D activities in pharmaceutical & biotechnology industry), restraints (High cost of custom humanized models, and regulatory compliance for ethical use of animal mode are expected to restrain the growth of this market during the forecast period), opportunities (Growing demand for humanized mouse models, preference for humanized PDX models, and emergence of CRISPR in biomedical research), challenges (Limitations of humanized mouse models and alternative methods for animal testing) are influencing the growth of humanized mouse and rat model market.
• Product Development/Innovation: Detailed insights on newly launched product, and technological assessment of the humanized mouse and rat model market.
• Market Development: Comprehensive information about lucrative markets – the report analyses the humanized mouse and rat model market across varied regions.
• Market Diversification: Exhaustive information about new product, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies product offerings of leading players like Charles River Laboratories (US), THE JACKSON LABORATORY (JAX) (US), Taconic Biosciences, Inc. (US), Inotiv (US), among others in the humanized mouse and rat model market. The report also helps stakeholders understand the pulse of humanized mouse and rat model market and provides them information on key market drivers, restraints, challenges, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（genetic）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（genetic）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?